Resources
20 Results (showing 1 - 10)
Results sorted by posted date (newest first)
Results sorted by posted date (newest first)
Posted 3/29/2024
A planning committee of the National Academies of Sciences, Engineering, and Medicine organized and conducted a two-day virtual public workshop that brought together data experts, program implementers and evaluators, and other key interested parties to explore data collection efforts, evidence gaps, and research needs on harm reduction for people who use drugs (PWUD).
Posted 12/1/2023 (updated 3/28/2024)
The Centers for Disease Control and Prevention and the National Organization of State Offices of Rural Health have joined with two philanthropic organizations with experience in minority communities – Well-being and Equity (WE) in the World and Well Being In the Nation (WIN) Network – to collaborate on guidelines for what it will take to bring health equity to rural areas.
Posted 7/28/2023 (updated 3/26/2024)
Researchers interviewed 20 individuals – clinicians, peer support specialists, cultural practitioners, and others familiar with OUD treatment – in a Minnesota tribal community. The Cascade of Care model measures the quality of outcomes at each stage of treatment, from diagnosis to long-term maintenance, and was first proposed in 1998 as an approach to care for HIV/AIDS.
Posted 2/7/2023 (updated 3/27/2024)
The Centers for Disease Control and Prevention (CDC) funded an evaluation study of post-overdose outreach programs in Massachusetts known as the PRONTO Study. This study group assessed the evidence on post-overdose outreach.
Posted 11/1/2022 (updated 3/27/2024)
Posted 4/12/2022 (updated 3/27/2024)
Since 1999, an estimated 841,000 people in the U.S. have died from a drug overdose. Beginning in March 2020, the COVID-19 pandemic significantly exacerbated the overdose crisis resulting in a 30% increase in 2020 compared to 2019. The majority of overdose deaths in the U.S. involve opioids, including nearly 71% of all overdose deaths in 2019.3 Despite high rates of overdose across the nation, overdose and overdose death are preventable. However, people at risk of overdose often face significant challenges accessing treatment and navigating systems of care. Local and state health departments are well-suited to lead and support efforts to prevent and respond to overdose and to link people to evidence-based treatment and services. Peer support services (PSS) are a valuable component of a growing number of overdose response and linkage to care initiatives that can be implemented and supported by local and state health departments.
Posted 4/12/2022 (updated 3/27/2024)
Describes the work of 26 2018-2021 Rural Health Opioid Program (RHOP) grantees in addressing the opioid epidemic through community-based consortiums. Highlights each project's achievements and identifies common themes of program impact.
Posted 3/16/2022 (updated 3/27/2024)
Background: Sharp exacerbations of the US overdose crisis are linked to polysubstance use of synthetic compounds. Xylazine is a veterinary tranquilizer, long noted in the street opioid supply of Puerto Rico, and more recently Philadelphia. Yet its national trends, geographic distribution, and health risks are poorly characterized. Methods: In this sequential mixed-methods study, xylazine was increasingly observed by ethnographers in Philadelphia among drug-sellers and people who inject drugs (PWID). Subsequently, we systematically searched for records describing xylazine-present overdose mortality across the US and assessed time trends and overlap with other drugs
Posted 12/22/2021 (updated 3/26/2024)
This guide provides rural health care leaders and teams with foundational knowledge, strategies, and resources to understand the impact of social determinants of health (SDOH) on patients and communities. It organizes key information and resources to help the busy manager support and lead education and discussion with front-line staff. This guide focuses on (1) understanding the need and opportunity around addressing SDOH, (2) using local data to support decision making, and (3) involving team members to plan and implement action steps.
Posted 5/26/2021 (updated 4/10/2024)
Opioid dependence is a chronic relapsing disorder with considerable individual and global public health burden. The current standard of care for opioid dependence includes treatment with methadone or sublingual (SL) buprenorphine or buprenorphine-naloxone (hereafter, buprenorphine), combined with psychosocial and behavioral support. Both medications are associated with reductions in mortality, illicit opioid use, bloodborne viral infections, and criminal behavior as well as better cost-effectiveness than no treatment or psychosocial treatment alone. Buprenorphine is a partial μ-opioid receptor agonist, enabling office-based treatment for nonsupervised or take-home use of the medication. However, SL formulations of buprenorphine are prone to nonmedical use (eg, injecting, diversion), prompting models of care, particularly in the early phases of treatment, requiring regular attendance at clinics or pharmacies for administration of doses.